These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Review on the influence of protocol design on clinical outcomes in rheumatoid arthritis treated with rituximab. Shetty S; Fisher MC; Ahmed AR Ann Pharmacother; 2013 Mar; 47(3):311-23. PubMed ID: 23447479 [TBL] [Abstract][Full Text] [Related]
63. Efficacy of interferon-gamma in patients with refractory bullous pemphigoid. Nakama T; Ishii N; Ono F; Hamada T; Yasumoto S; Hashimoto T J Dermatol; 2007 Nov; 34(11):737-45. PubMed ID: 17973812 [TBL] [Abstract][Full Text] [Related]
64. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. Reguiai Z; Tabary T; Maizières M; Bernard P J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417 [TBL] [Abstract][Full Text] [Related]
65. Mortality and clinical response of patients with bullous pemphigoid treated with rituximab. Yoo DS; Lee JH; Kim SC; Kim JH Br J Dermatol; 2021 Jul; 185(1):210-212. PubMed ID: 33657641 [No Abstract] [Full Text] [Related]
66. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Cartin-Ceba R; Golbin JM; Keogh KA; Peikert T; Sánchez-Menéndez M; Ytterberg SR; Fervenza FC; Specks U Arthritis Rheum; 2012 Nov; 64(11):3770-8. PubMed ID: 22730028 [TBL] [Abstract][Full Text] [Related]
67. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry. Puéchal X; Gottenberg JE; Berthelot JM; Gossec L; Meyer O; Morel J; Wendling D; de Bandt M; Houvenagel E; Jamard B; Lequerré T; Morel G; Richette P; Sellam J; Guillevin L; Mariette X; Arthritis Care Res (Hoboken); 2012 Mar; 64(3):331-9. PubMed ID: 22076726 [TBL] [Abstract][Full Text] [Related]
68. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients. Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525 [TBL] [Abstract][Full Text] [Related]
69. Low-dose rituximab is effective in pemphigus. Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609 [TBL] [Abstract][Full Text] [Related]
70. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey. Brah S; Chiche L; Fanciullino R; Bornet C; Mancini J; Schleinitz N; Jean R; Kaplanski G; Harlé JR; Durand JM Ann Hematol; 2012 Feb; 91(2):279-85. PubMed ID: 21710166 [TBL] [Abstract][Full Text] [Related]
71. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243 [TBL] [Abstract][Full Text] [Related]
78. Successful treatment of refractory autoimmune hepatitis with rituximab. D'Agostino D; Costaguta A; Álvarez F Pediatrics; 2013 Aug; 132(2):e526-30. PubMed ID: 23821693 [TBL] [Abstract][Full Text] [Related]
79. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062 [TBL] [Abstract][Full Text] [Related]
80. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Gürcan HM; Ahmed AR Br J Dermatol; 2009 Oct; 161(4):723-31. PubMed ID: 19548961 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]